Baseline bone mineral density testing among breast cancer patients prescribed aromatase inhibitors (AIs).

被引：0
|
作者：
Charlson, John A. [1 ]
Smith, Elizabeth [1 ]
Laud, Purushottam [1 ]
Smallwood, Alicia [1 ]
Neuner, Joan [1 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6642
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important
    Markopoulos, Christos
    BREAST CANCER RESEARCH, 2010, 12 (04)
  • [32] Managing bone health in women with breast cancer under adjuvant treatment with aromatase inhibitors: pretreatment bone mineral density is important
    Christos Markopoulos
    Breast Cancer Research, 12
  • [33] EVALUATION OF BONE MINERAL DENSITY (BMD) IN EARLY BREAST CANCER (EBC) PATIENTS TREATED WITH UP-FRONT OR SWITCH SCHEDULES OF AROMATASE INHIBITORS (AIS): RESULTS OF A SINGLE CENTRE RETROSPECTIVE STUDY
    Seminara, P.
    Iannace, A.
    Manna, G.
    Losanno, T.
    Emiliani, A.
    Franzese, E.
    Frati, L.
    ANNALS OF ONCOLOGY, 2012, 23 : 105 - 106
  • [34] The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors
    Bailey, S.
    Mhango, G.
    Lin, J. J.
    OSTEOPOROSIS INTERNATIONAL, 2022, 33 (09) : 1989 - 1997
  • [35] The impact of bone mineral density screening on incident fractures and healthcare resource utilization among postmenopausal breast cancer survivors treated with aromatase inhibitors
    S. Bailey
    G. Mhango
    J. J. Lin
    Osteoporosis International, 2022, 33 : 1989 - 1997
  • [36] Evaluation of bone mineral density in the monitoring of the effects of breast cancer treatment with aromatase inhibitors: The importance of the least significant change
    Pacifici, Stefano
    IMAGEN DIAGNOSTICA, 2014, 5 (02): : 49 - 54
  • [37] Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer
    Sakaguchi, Koichi
    Ono, Hisako
    Nakatsukasa, Katsuhiko
    Ishikawa, Takashi
    Hasegawa, Yoshie
    Takahashi, Masato
    Niikura, Naoki
    Koizumi, Kei
    Sakurai, Teruhisa
    Shigematsu, Hideo
    Takahashi, Shunji
    Taira, Shinichiro
    Suzuki, Masato
    Narui, Kazutaka
    Miura, Daishu
    Yamada, Kimito
    Yoshimura, Mana
    Shioya, Hisashi
    Konishi, Eiichi
    Isao, Yokota
    Imai, Kojiro
    Fujikawa, Kei
    Taguchi, Tetsuya
    MEDICINE, 2019, 98 (32)
  • [38] Identifying the genetic basis for resistance to aromatase inhibitors (AIs) in metastatic breast cancer ( mBC) patients
    Singh, Neeraj
    Agrawal, Smita
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Low Rates of Bone Mineral Density Testing in Medicare Beneficiaries with Breast Cancer Starting Aromatase Inhibitor Therapy.
    Siricilla, Mamatha
    Luo, Ruili
    Elting, Linda
    Suarez-Almazor, Maria E.
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S47 - S47
  • [40] Utilization of bone mineral density testing among breast cancer survivors in British Columbia, Canada
    Tseng, O. L.
    Dawes, M. G.
    Spinelli, J. J.
    Gotay, C. C.
    McBride, M. L.
    OSTEOPOROSIS INTERNATIONAL, 2017, 28 (12) : 3439 - 3449
12345